Lactic Acid

Summary

Lactic Acid (CHEMBL1200559) is an approved small molecule (ATC G01AD01); indicated across 4 conditions including tonsillitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G01AD01
• Indications: 4 conditions
• Clinical trials: 99
• Chemistry: 90.08 Da · C3H6O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200559
Name	Lactic Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	612
ChEBI	CHEBI:78320
ATC	G01AD01
Molecular formula	C3H6O3
Molecular weight	90.08
InChIKey	JVTAAEKCZFNVCJ-UHFFFAOYSA-N

SMILES: CC(C(=O)O)O

IUPAC name: 2-hydroxypropanoic acid

ChEBI definition: A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the α-hydrogens is replaced by a hydroxy group.

Other ChEBI roles (chemical / environmental): Daphnia magna metabolite, algal metabolite.

Also known as: Acidum lacticum, Dl- lactic acid, Dl-lactic acid, E 270, E-270, E270, FEMA NO. 2611, HIPURE 88, INS NO.270, INS-270, L-lactic acid or dl-lactic acid, Lactic acid

Patent coverage: 428,796 distinct patent families (1,162,486 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,162,449 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Cellular tumor antigen p53.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TP53	7.6	Potency	25.1	nM	CHEMBL_ACT_4878748

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
tonsillitis	1	MONDO:0001039	HP:0011110

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 99.

Phase distribution

Phase	Trials
Not specified	51
PHASE4	18
PHASE3	15
PHASE2	8
PHASE2/PHASE3	3
PHASE1	2
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06260878	PHASE4	RECRUITING	Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
NCT07124130	PHASE4	RECRUITING	Lactated Ringer’s and Dextrose 5% vs Only Lactated Ringer’s in Labor
NCT07240701	PHASE4	NOT_YET_RECRUITING	Normal Saline Versus Ringer’s Lactate for Initial Fluid Resuscitation in Sepsis
NCT00542516	PHASE4	COMPLETED	Comparison Between Two Techniques of Volemic Expansion in Hip Replacement Arthroplasty
NCT00712868	PHASE4	COMPLETED	Acceptability of Lactacyd Femina
NCT00771121	PHASE4	UNKNOWN	Effect of Moisturizing Creams on Skin Barrier Function
NCT00797589	PHASE4	COMPLETED	Effect of Prime Solution on Fluid Balance After Open Heart Surgery
NCT01387477	PHASE4	WITHDRAWN	Lactate to Treat Hypoglycemia
NCT01632046	PHASE4	COMPLETED	Administration of pH-Neutral Peritoneal Dialysis Solutions Containing Lactate or Bicarbonate in Children
NCT01692769	PHASE4	COMPLETED	Trial Of Normal Saline Versus Ringer’s Lactate In Paediatric Trauma Patients
NCT03764085	PHASE4	COMPLETED	Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis.
NCT03771170	PHASE4	COMPLETED	Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis
NCT03799250	PHASE4	UNKNOWN	Fluid Management in the Post Anesthesia Care Unit
NCT03824457	PHASE4	COMPLETED	Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Pneumonia
NCT04152096	PHASE4	COMPLETED	Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Burns
NCT04512950	PHASE4	COMPLETED	Crystalloid FLUID Choices for Resuscitation of Hospitalized Patients
NCT05259007	PHASE4	UNKNOWN	Effect of Propolis on Patients Infected With H. Pylori
NCT05610254	PHASE4	COMPLETED	The Cold Fluids Study
NCT00529490	PHASE3	COMPLETED	Efficacy, Safety of Hypertonic Lactate Soln. as Fluid Resuscitation Compared With Ringer’s Lactate in Post-CABG Pats
NCT00529711	PHASE3	COMPLETED	The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients
NCT00761800	PHASE3	COMPLETED	Dermacyd Teen Care Tangerina Mix - Compatibility
NCT00783640	PHASE3	COMPLETED	Dermacyd Femina (Lactic Acid) Pocket BR - Photo Evaluation
NCT00783861	PHASE3	COMPLETED	Dermacyd Femina (Lactic Acid) Pocket BR - Compatibility
NCT00783939	PHASE3	COMPLETED	Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Safety.
NCT00784069	PHASE3	COMPLETED	Dermacyd Breeze (Lactic Acid) Pocket BR - Photo Evaluation
NCT00784121	PHASE3	COMPLETED	Dermacyd Breeze (Lactic Acid) Pocket BR - Compatibility
NCT00966628	PHASE3	UNKNOWN	Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS)
NCT01433276	PHASE3	COMPLETED	Efficacy, Safety of Solution Containing Hyperosmolar Sodium Lactate Infusion for Resuscitation of Patients With Hemorrhagic Shock
NCT02634255	PHASE3	UNKNOWN	The Onset Time of Rocuronium in Emergency and Elective Surgery
NCT02709044	PHASE2/PHASE3	UNKNOWN	Fluid Resuscitation in Acute Pancreatitis
NCT03043131	PHASE3	UNKNOWN	Comparative Analysis Between Ringer’s Lactate vs Plasma Lyte-A as Cardiopulmonary Bypass Prime
NCT03118362	PHASE3	COMPLETED	Fluid Resuscitation in Burn Patients
NCT05223361	PHASE3	COMPLETED	Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery
NCT05658406	PHASE2/PHASE3	COMPLETED	Supplemental Perioperative Intravenous Crystalloids for Postoperative Nausea and Vomiting in Children Undergoing Oncological Surgery
NCT06110429	PHASE3	UNKNOWN	Sodium Lactate Versus Hypertonic Saline Solution in the Treatment of Intracranial Hypertensive Episodes in Severe Brain Injured Patients
NCT06461390	PHASE2/PHASE3	COMPLETED	The Effect of Early Norepinephrine on Stroke Volume Index, Cardiac Index, Lactate, and Arterial Elastance in Pediatric Septic Shock
NCT06487299	PHASE2	NOT_YET_RECRUITING	Iron Administration Via Colonic TET Combined With WMT for ID
NCT00425334	PHASE2	COMPLETED	Safety Study of Hemospan® in Prostatectomy Patients
NCT00494949	PHASE1/PHASE2	COMPLETED	Increasing Dose Safety Study of Hemospan in Orthopedic Surgery Patients
NCT00679562	PHASE2	COMPLETED	Lactacyd Radiance (Lactic Acid) Prophetic Patch Test

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).